As an oral receptor tyrosine kinase inhibitor, it inhibits intracellular serine/threonine kinases (including the Raf/MEK/ERK signaling pathway) and receptor tyrosine kinases [RTKs; including vascular endothelial growth factor receptors (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-β, c-KIT, FMS-like tyrosine kinase 3 (FLT-3), and rearranged during transfection (RET)], thereby inhibiting tumor growth and angiogenesis (Tang et al., 2020). Here, MARK2 is linked to neoplasm.